CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 122,056 | ||
| 2025-05-19 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −5,000 | $16.31 | $82K | 985,188 |
| 2025-05-19 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −5,000 | $16.49 | $82K | 972,892 |
| 2025-05-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −6,173 | $18.30 | $113K | 310,470 |
| 2025-05-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −390 | $19.40 | $8K | 310,080 |
| 2025-05-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −104 | $19.87 | $2K | 309,976 |
| 2025-05-02 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −2,470 | $20.01 | $49K | 990,188 |
| 2025-05-02 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −2,170 | $20.00 | $43K | 977,892 |
| 2025-05-01 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −5,030 | $20.07 | $101K | 992,658 |
| 2025-05-01 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −5,330 | $20.08 | $107K | 980,062 |
| 2025-04-28 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,250 | $2.48 | $8K | 26,250 |
| 2025-04-28 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,181 | $18.68 | $59K | 23,069 |
| 2025-04-28 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −69 | $19.12 | $1K | 23,000 |
| 2025-04-28 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 125,306 | ||
| 2025-04-21 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −4,670 | $16.03 | $75K | 998,018 |
| 2025-04-21 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −330 | $16.72 | $6K | 997,688 |
| 2025-04-17 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −5,000 | $16.42 | $82K | 985,392 |
| 2025-04-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −3,756 | $17.81 | $67K | 319,554 |
| 2025-04-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −2,763 | $18.29 | $51K | 316,791 |
| 2025-04-07 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −148 | $19.27 | $3K | 316,643 |
Page 11 of 37 · 724 trades